Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Stattin P) "

Sökning: WFRF:(Stattin P)

Sortera/gruppera träfflistan
  • Wang, Zhaoming, et al. (författare)
  • Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33
  • 2014
  • Ingår i: Human Molecular Genetics. - 0964-6906 .- 1460-2083. ; 23:24, s. 6616-6633
  • Tidskriftsartikel (refereegranskat)abstract
    • Genome-wide association studies (GWAS) have mapped risk alleles for at least 10 distinct cancers to a small region of 63 000 bp on chromosome 5p15.33. This region harbors the TERT and CLPTM1L genes; the former encodes the catalytic subunit of telomerase reverse transcriptase and the latter may play a role in apoptosis. To investigate further the genetic architecture of common susceptibility alleles in this region, we conducted an agnostic subset-based meta-analysis (association analysis based on subsets) across six distinct cancers in 34 248 cases and 45 036 controls. Based on sequential conditional analysis, we identified as many as six independent risk loci marked by common single-nucleotide polymorphisms: five in the TERT gene (Region 1: rs7726159, P = 2.10 × 10(-39); Region 3: rs2853677, P = 3.30 × 10(-36) and PConditional = 2.36 × 10(-8); Region 4: rs2736098, P = 3.87 × 10(-12) and PConditional = 5.19 × 10(-6), Region 5: rs13172201, P = 0.041 and PConditional = 2.04 × 10(-6); and Region 6: rs10069690, P = 7.49 × 10(-15) and PConditional = 5.35 × 10(-7)) and one in the neighboring CLPTM1L gene (Region 2: rs451360; P = 1.90 × 10(-18) and PConditional = 7.06 × 10(-16)). Between three and five cancers mapped to each independent locus with both risk-enhancing and protective effects. Allele-specific effects on DNA methylation were seen for a subset of risk loci, indicating that methylation and subsequent effects on gene expression may contribute to the biology of risk variants on 5p15.33. Our results provide strong support for extensive pleiotropy across this region of 5p15.33, to an extent not previously observed in other cancer susceptibility loci.
  • Hammarsten, P., et al. (författare)
  • Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome
  • 2019
  • Ingår i: Modern Pathology. - : NATURE PUBLISHING GROUP. - 0893-3952 .- 1530-0285. ; 32
  • Tidskriftsartikel (refereegranskat)abstract
    • Based on gene-expression profiles, prostate tumors can be subdivided into subtypes with different aggressiveness and response to treatment. We investigated if similar clinically relevant subgroups can be identified simply by the combination of two immunohistochemistry markers: one for tumor cell differentiation (prostate specific antigen, PSA) and one for proliferation (Ki67). This was analyzed in men with prostate cancer diagnosed at transurethral resection of the prostate 1975–1991 (n = 331) where the majority was managed by watchful waiting. Ki67 and PSA immunoreactivity was related to outcome and to tumor characteristics previously associated with prognosis. Increased Ki67 and decreased PSA were associated with poor outcome, and they provided independent prognostic information from Gleason score. A combinatory score for PSA and Ki67 immunoreactivity was produced using the median PSA and Ki67 levels as cut-off (for Ki67 the upper quartile was also evaluated) for differentiation into subgroups. Patients with PSA low/Ki67 high tumors showed higher Gleason score, more advanced tumor stage, and higher risk of prostate cancer death compared to other patients. Their tumor epithelial cells were often ERG positive and expressed higher levels of ErbB2, phosphorylated epidermal growth factor receptor (pEGF-R) and protein kinase B (pAkt), and their tumor stroma showed a reactive response with type 2 macrophage infiltration, high density of blood vessels and hyaluronic acid, and with reduced levels of caveolin-1, androgen receptors, and mast cells. In contrast, men with PSA high/Ki67 low tumors were characterized by low Gleason score, and the most favorable outcome amongst PSA/Ki67-defined subgroups. Men with PSA low/Ki67 low tumors showed clinical and tumor characteristics intermediate of the two groups above. A combinatory PSA/Ki67 immunoreactivity score identifies subgroups of prostate cancers with different epithelial and stroma phenotypes and highly different outcome but the clinical usefulness of this approach needs to be validated in other cohorts. © 2019, The Author(s).
  • Hagglof, C., et al. (författare)
  • TMPRSS2-ERG Expression Predicts Prostate Cancer Survival and Associates with Stromal Biomarkers
  • 2014
  • Ingår i: Plos One. - 1932-6203. ; 9:2
  • Tidskriftsartikel (refereegranskat)abstract
    • The TMPRSS2-ERG gene fusion is found in approximately half of all prostate cancers. The functional and prognostic significance of TMPRSS2-ERG is, however, not fully understood. Based on a historical watchful waiting cohort, an association between TMPRSS2-ERG, evaluated as positive immune staining, and shorter survival of prostate cancer patients was identified. Expression of ERG was also associated with clinical markers such as advanced tumor stage, high Gleason score, presence of metastasis and prognostic tumor cell markers such as high Ki67, pEGFR and pAkt. Novel associations between TMPRSS2-ERG and alterations in the tumor stroma, for example, increased vascular density, hyaluronan and PDGFR beta and decreased Caveolin-1, all known to be associated with an aggressive disease, were found. The present study suggests that the TMPRSS2-ERG fusion gene is associated with a more aggressive prostate cancer phenotype, supported by changes in the tumor stroma.
  • Hedlund, P. O., et al. (författare)
  • Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer : Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5
  • 2008
  • Ingår i: Scandinavian Journal of Urology and Nephrology. - 0036-5599 .- 1651-2065. ; 42:3, s. 220-229
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective. To compare parenteral estrogen therapy in the form of high-dose polyestradiol phosphate (PEP, Estradurin®) with combined androgen deprivation (CAD) in the treatment of prostate cancer patients with skeletal metastases. The aim of the study was to compare anticancer efficacy and adverse events, especially cardiovascular events. Material and methods. In total, 910 eligible patients with T0-4, NX, M1, G1-3 prostate cancer with an Eastern Cooperative Oncology Group performance status of 0-2 were randomized to treatment with either PEP 240mg i.m. twice a month for 2months and thereafter monthly, or flutamide (Eulexin®) 250mg t.i.d. per os in combination with either triptorelin (Decapeptyl®) 3.75mg i.m. per month or on an optional basis bilateral orchidectomy. Results. At this final evaluation of the trial 855 of the 910 patients were dead. There was no difference between the treatment groups in terms of biochemical or clinical progression-free survival or in overall or disease-specific survival. There was no difference in cardiovascular mortality, but a significant increase in non-fatal cardiovascular events in the PEP arm (p<0.05) predominantly caused by an increase in ischemic heart and heart decompensation events. There were 18 grave skeletal events in the CAD group but none in the PEP group (p=0.001). Conclusions. PEP has an anticancer efficacy equal to CAD and does not increase cardiovascular mortality in metastasized patients, but carries a significant risk of non-fatal cardiovascular events, which should be balanced against the skeletal complications in the CAD group. It is feasible to use Estradurin in the primary or secondary endocrine treatment of metastasized patients without prominent cardiac risk factors and especially those with osteoporosis. © 2008 Taylor & Francis.
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (282)
konferensbidrag (24)
annan publikation (2)
forskningsöversikt (2)
recension (1)
Typ av innehåll
refereegranskat (271)
övrigt vetenskapligt (40)
Stattin, P (306)
Stattin, Pär (224)
Garmo, H (99)
Adolfsson, J. (89)
Garmo, Hans (66)
Adolfsson, Jan (61)
visa fler...
Van Hemelrijck, M (61)
Holmberg, L (60)
LAMBE, M (57)
Robinson, D. (53)
Bratt, O (52)
Egevad, L (51)
Stattin, Par (49)
Gronberg, H (48)
Wiklund, F (46)
Bratt, Ola (45)
Van Hemelrijck, Miek ... (44)
Holmberg, Lars (43)
Wiklund, Fredrik (39)
Bergh, A (36)
Lambe, Mats (34)
Robinson, David (34)
Grönberg, Henrik (33)
Egevad, Lars (32)
Hallmans, G (31)
Bill-Axelson, A (30)
Drevin, L (27)
Akre, O (26)
Adami, Hans Olov (25)
Adami, HO (25)
Hallmans, Göran (25)
Xu, Jianfeng (25)
Carlsson, S (24)
Hugosson, J (24)
Xu, JF (24)
Gronberg, Henrik (23)
Bill-Axelson, Anna (21)
Bergh, Anders (21)
Isaacs, William B (21)
Johansson, JE (20)
Zheng, SL (20)
Granfors, T (20)
Franck Lissbrant, In ... (20)
Holmberg, E. (19)
Folkvaljon, Y (19)
Kaaks, R. (18)
Drevin, Linda (18)
Akre, Olof (17)
Zheng, S Lilly (17)
Wikstrom, P (17)
visa färre...
Umeå universitet (185)
Karolinska Institutet (121)
Uppsala universitet (115)
Göteborgs universitet (53)
Lunds universitet (37)
Mälardalens högskola (18)
visa fler...
Örebro universitet (8)
Linköpings universitet (6)
Luleå tekniska universitet (2)
Högskolan Kristianstad (1)
Stockholms universitet (1)
Ersta Sköndal Bräcke högskola (1)
Högskolan Dalarna (1)
visa färre...
Engelska (311)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (229)
Lantbruksvetenskap (6)
Naturvetenskap (2)
Samhällsvetenskap (2)


pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy